🇺🇸 PTCT — PTC Therapeutics, Inc.

Salud Compra
← Volver

Precio actual

68,97 USD

Máx. histórico

89,55

118 días

Caída desde máximo

-22,98%

Rango 52 semanas

58,80 – 90,87

Variación hoy

+1,25%

Cierre anterior

68,12

Rango de hoy

66,87 – 70,11

Volumen hoy

1.266.047

Peor caída histórica

-94,60%

17/03/2015 → 03/11/2016

Recuperado en 3305 días

Volatilidad anualizada ⓘ

72,98%

Información
Nombre completo
PTC Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
991
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
100,47 USD (puede no estar actualizado)
Primera cotización
20/06/2013
Precio actualizado
hace 18 horas
Sobre la empresa

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
04/01/2018 17,94 18,16 17,42 17,99 -0,11% 4,15% 581.300
03/01/2018 17,67 18,17 17,50 18,01 +3,15% 3,79% 969.000
02/01/2018 16,86 17,64 16,38 17,46 +4,68% 7,47% 747.200
29/12/2017 17,04 17,20 16,67 16,68 -0,18% 3,11% 607.400
28/12/2017 16,68 16,77 16,40 16,71 +0,60% 2,22% 501.900
27/12/2017 16,61 16,68 16,32 16,61 +0,06% 2,17% 546.500
26/12/2017 16,58 16,71 16,37 16,60 -0,24% 2,05% 336.000
22/12/2017 16,50 16,75 16,13 16,64 +1,59% 3,76% 364.600
21/12/2017 16,23 16,53 16,20 16,38 +0,49% 2,03% 329.100
20/12/2017 16,32 16,49 16,15 16,30 +0,37% 2,08% 324.200
19/12/2017 16,20 16,67 16,08 16,24 +0,12% 3,64% 386.100
18/12/2017 16,17 16,41 15,97 16,22 +0,56% 2,72% 428.100
15/12/2017 15,99 16,48 15,69 16,13 +1,13% 4,94% 2.363.000
14/12/2017 16,62 16,73 15,67 15,95 -4,20% 6,38% 950.800
13/12/2017 16,00 16,82 16,00 16,65 +4,45% 5,09% 871.600
12/12/2017 16,25 16,37 15,60 15,94 -1,91% 4,74% 629.500
11/12/2017 16,82 16,87 16,23 16,25 -2,69% 3,80% 571.400
08/12/2017 16,85 16,96 16,57 16,70 -0,30% 2,31% 604.900
07/12/2017 16,17 16,81 16,02 16,75 +3,97% 4,89% 782.900
06/12/2017 15,79 16,23 15,67 16,11 +0,88% 3,55% 522.700
05/12/2017 15,73 16,46 15,73 15,97 +1,27% 4,64% 400.700
04/12/2017 15,95 16,53 15,71 15,77 -0,06% 5,11% 512.400
01/12/2017 15,98 16,16 15,22 15,78 -1,07% 5,88% 987.500
30/11/2017 15,86 16,20 15,73 15,95 +0,19% 2,96% 1.545.300
29/11/2017 16,16 16,25 15,75 15,92 -1,49% 3,09% 389.000
28/11/2017 16,30 16,45 16,01 16,16 -0,19% 2,72% 641.000
27/11/2017 16,52 16,71 16,14 16,19 -2,41% 3,48% 605.900
24/11/2017 16,00 16,67 15,84 16,59 +4,73% 5,19% 376.300
22/11/2017 15,84 16,06 15,70 15,84 +0,32% 2,24% 873.300
21/11/2017 15,68 16,00 15,62 15,79 +0,38% 2,42% 881.900